GRANULES INDIA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 401.8 INR | +0.49% |
|
+0.94% | -0.89% |
| May. 15 | Transcript : Granules India Limited, Q4 2024 Earnings Call, May 15, 2024 | |
| May. 15 | Granules India Posts Decline in Fiscal Q4 Consolidated Net Profit, Revenue | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Granules India Limited is an India-based pharmaceutical manufacturing company. The Company operates through its pharmaceuticals products segment. Its geographical segments include within India and outside India. The Company has its presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). It has over eight manufacturing facilities, approximately seven of which are located in India and one in the United States. The Company sells its products in the global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific and India. The Companyâs wholly owned subsidiaries include Granules USA Inc, Granules Pharmaceuticals Inc, Granules Europe Limited and Granules Lifesciences Private Limited.
Sector
Pharmaceuticals
Calendar
2024-08-06
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
401.8
INR
Average target price
471.6
INR
Spread / Average Target
+17.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.89% | 1.16B | |
| +32.09% | 694B | |
| +29.39% | 593B | |
| -1.34% | 371B | |
| +20.34% | 331B | |
| +7.39% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.49% | 169B |
- Stock Market
- Equities
- GRANULES Stock
- News Granules India Limited
- Granules India Gets US FDA Nod for Hypertension Treatment Drug
